Moderna has withdrawn the BLA for mRNA-1083, a combination vaccine against seasonal influenza and SARS-CoV-2, after consulting with FDA.

dDepartment of Disease Control and Prevention, Pasteur Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam ...

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID. Please note: If you switch to a different device, you may be ...

aDepartment of Infectious Diseases and Respiratory Medicine, Charité—Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany bInstitute of Virology, ...

The BLA for mRNA-1083 will be resubmitted later this year once vaccine efficacy data from an ongoing phase 3 trial assessing mRNA-1010 are available. Moderna has withdrawn the Biologics License ...

Components of Revenue excluded from the Full Year 2025 Revenue Framework are described below. Sanofi Supply Sales Novavax will sell Nuvaxovid commercial supply to Sanofi for the 2025-2026 vaccination ...

Raises full year 2025 revenue framework to between $975 million and $1,025 million Reiterates full year 2025 financial guidance for combined R&D and SG&A expenses of between $475 million and $525 ...

A two-in-one mRNA vaccine against influenza and COVID-19 showed good reactogenicity and safety results compared with vaccines already on the market. (JAMA) New York reported a record high of 25 ...

Nuvaxovid was the primary theme running through the call, in which executives also touched on the company’s earlier-stage pipeline—including a combination COVID-19/flu vaccine currently in Phase III ...